ABT-378/r
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Despite major advances in HIV research, eradication of HIV from the body is not yet possible. However, current antiretroviral…
On March 9, 2001, Health Canada granted permission to Abbott Laboratories for the sale of Kaletra (a combination of protease…
Details and information sources on Kaletra (lopinavir plus low-dose ritonavir), a protease inhibitor approved last week.
The new protease inhibitor ABT-378/r, which is ABT-378 combined with a small amount of Ritonavir, is available to a limited…
Despite the promise of highly active antiretroviral therapies (HAART) to potentially suppress HIV, the ability of the virus to…
Several sessions at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) presented results of…